Imiglucerase (Cerezyme)

Cerezyme (imiglucerase) is covered only for the FDA‑approved indication of Type 1 Gaucher disease and is not covered for other indications. Coverage requires diagnostic confirmation by deficient β‑glucocerebrosidase activity in leukocytes/fibroblasts or molecular GBA mutation, prescription by or consultation with a geneticist, endocrinologist, metabolic disorder/lysosomal storage disorder specialist, documentation that policy coverage and safety criteria are met, dosing limited to 60 U/kg IV no more frequently than every 2 weeks, and authorization is limited to 1 year.

"Cerezyme is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.